Compounding Pharmacies: FDA's 2026 Fee Squeeze Hits Hard
Published Date: 7/30/2025
Notice
Summary
If you run a drug-compounding outsourcing facility, the FDA just set the fees for fiscal year 2026. Small businesses will pay $6,829, while bigger ones owe $20,726, plus $20,486 for any reinspections. These fees help keep drug safety in check, so get ready to pay on time and keep your facility in tip-top shape!
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
Small Business Establishment Fee Set
If you run a drug‑compounding outsourcing facility and are classified as a small business, the FDA set the FY 2026 annual establishment fee at $6,829. This is the yearly amount your facility must pay to be registered as an outsourcing facility under the Federal Food, Drug, and Cosmetic Act.
Non‑Small Business Establishment Fee
If you run a drug‑compounding outsourcing facility that is not a small business, the FDA set the FY 2026 annual establishment fee at $20,726. This is the yearly fee larger outsourcing facilities must pay to be registered under the Federal Food, Drug, and Cosmetic Act.
Reinspection Fee Charged Per Reinspection
If your outsourcing facility is reinspected, the FDA set the FY 2026 reinspection fee at $20,486 for each reinspection. You must pay this fee for every reinspection conducted during FY 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-14409, Animal Generic Drug User Fee Program Rates and Payment Procedures for Fiscal Year 2026
The FDA is setting the fees and payment rules for companies making generic animal drugs in fiscal year 2026. If you create or sponsor these generic animal medicines, expect some updated costs and deadlines to keep your products moving. These changes help the FDA keep things running smoothly and on time for safer, affordable animal meds.
Next: 2025-14411, Generic Drug User Fee Rates for Fiscal Year 2026
Starting in fiscal year 2026, companies making generic drugs will see updated fees they need to pay to the FDA. These fees affect drug applications, manufacturing sites, and related programs, helping the FDA keep generic medicines safe and available. The new rates kick in soon, so businesses should get ready to budget for these changes.